Syros Pharmaceuticals (NASDAQ:SYRS) Research Coverage Started at StockNews.com

StockNews.com started coverage on shares of Syros Pharmaceuticals (NASDAQ:SYRS) in a research note published on Wednesday. The brokerage issued a sell rating on the stock.

A number of other equities analysts have also commented on SYRS. JMP Securities reiterated a “market perform” rating on shares of Syros Pharmaceuticals in a research note on Wednesday, November 13th. HC Wainwright reissued a “neutral” rating and issued a $1.00 price objective (down from $6.00) on shares of Syros Pharmaceuticals in a research report on Wednesday, November 13th. TD Cowen reaffirmed a “hold” rating on shares of Syros Pharmaceuticals in a research report on Wednesday, November 13th. Finally, Brookline Capital Management reiterated a “hold” rating on shares of Syros Pharmaceuticals in a research note on Wednesday, November 13th. One research analyst has rated the stock with a sell rating, four have given a hold rating and one has assigned a buy rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Hold” and a consensus target price of $3.33.

Syros Pharmaceuticals Stock Up 7.1 %

Shares of SYRS stock opened at $0.23 on Wednesday. The company has a market capitalization of $6.04 million, a price-to-earnings ratio of -0.07 and a beta of 1.31. The company has a debt-to-equity ratio of 1.97, a quick ratio of 2.25 and a current ratio of 2.25. The stock’s 50 day simple moving average is $0.58 and its 200 day simple moving average is $2.35. Syros Pharmaceuticals has a twelve month low of $0.18 and a twelve month high of $7.96.

Syros Pharmaceuticals (NASDAQ:SYRS) last issued its quarterly earnings data on Thursday, October 31st. The company reported ($0.68) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.76) by $0.08. During the same quarter last year, the firm earned ($1.35) earnings per share. As a group, research analysts predict that Syros Pharmaceuticals will post -2.94 EPS for the current year.

Insider Activity

In other Syros Pharmaceuticals news, Director Nancy A. Simonian sold 134,713 shares of the firm’s stock in a transaction dated Monday, November 25th. The shares were sold at an average price of $0.27, for a total transaction of $36,372.51. Following the completion of the transaction, the director now owns 41,070 shares in the company, valued at $11,088.90. This trade represents a 76.64 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 12.26% of the stock is owned by company insiders.

Hedge Funds Weigh In On Syros Pharmaceuticals

A number of hedge funds have recently modified their holdings of SYRS. GSA Capital Partners LLP bought a new stake in Syros Pharmaceuticals in the third quarter valued at $34,000. Acadian Asset Management LLC grew its holdings in shares of Syros Pharmaceuticals by 101.5% during the second quarter. Acadian Asset Management LLC now owns 34,578 shares of the company’s stock worth $178,000 after purchasing an additional 17,416 shares during the last quarter. Finally, Exome Asset Management LLC raised its holdings in shares of Syros Pharmaceuticals by 87.6% in the third quarter. Exome Asset Management LLC now owns 298,575 shares of the company’s stock valued at $642,000 after buying an additional 139,400 shares during the last quarter. 91.47% of the stock is owned by institutional investors and hedge funds.

About Syros Pharmaceuticals

Syros Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development of treatment for hematologic malignancies. The company's lead product candidates are Tamibarotene, a selective retinoic acid receptor alpha agonist, which is in Phase III clinical trial for genomically defined subset of patients with myelodysplastic syndrome and Phase II clinical trial for patients with acute myeloid leukemia; SY-2101, a novel oral form of arsenic trioxide for treating patients with acute promyelocytic leukemia; and SY-5609, a cyclin-dependent kinase 7 inhibitor, which is in a Phase I clinical trial in patients with select advanced solid tumors.